肿瘤溶瘤病毒诱导的抗肿瘤免疫的药物调节。
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.
机构信息
Center for Innovative Cancer Research, Ottawa Hospital Research Institute , Ottawa, ON , Canada ; Faculty of Medicine, University of Ottawa , Ottawa, ON , Canada.
出版信息
Front Oncol. 2014 Jul 23;4:191. doi: 10.3389/fonc.2014.00191. eCollection 2014.
Abstract
Oncolytic viruses (OVs) not only kill cancer cells by direct lysis but also generate a significant anti-tumor immune response that allows for prolonged cancer control and in some cases cures. How to best stimulate this effect is a subject of intense investigation in the OV field. While pharmacological manipulation of the cellular innate anti-viral immune response has been shown by several groups to improve viral oncolysis and spread, it is increasingly clear that pharmacological agents can also impact the anti-tumor immune response generated by OVs and related tumor vaccination strategies. This review covers recent progress in using pharmacological agents to improve the activity of OVs and their ability to generate robust anti-tumor immune responses.
摘要
溶瘤病毒 (OVs) 不仅可以通过直接裂解杀死癌细胞，还可以产生显著的抗肿瘤免疫反应，从而实现对癌症的长期控制，甚至在某些情况下可以治愈癌症。如何最好地刺激这种效应是 OV 领域中一个研究热点。虽然已有多个研究小组证明，通过药理学手段来调节细胞固有抗病毒免疫反应，可以提高病毒的溶瘤作用和传播能力，但越来越明显的是，药理学药物也会影响 OV 产生的抗肿瘤免疫反应以及相关的肿瘤疫苗策略。本文综述了近年来利用药理学手段来提高 OV 的活性及其产生强大抗肿瘤免疫反应的能力的最新进展。
相似文献
1
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.
Front Oncol. 2014 Jul 23;4:191. doi: 10.3389/fonc.2014.00191. eCollection 2014.
2
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Viruses. 2016 Jan 6;8(1):9. doi: 10.3390/v8010009.
3
Oncolytic Viruses and the Immune System: The Dynamic Duo.
Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358. doi: 10.1016/j.omtm.2020.01.001. eCollection 2020 Jun 12.
4
Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy.
Expert Opin Biol Ther. 2021 Feb;21(2):183-189. doi: 10.1080/14712598.2020.1811848. Epub 2020 Sep 14.
5
The pros and cons of interferons for oncolytic virotherapy.
Cytokine Growth Factor Rev. 2020 Dec;56:49-58. doi: 10.1016/j.cytogfr.2020.07.002. Epub 2020 Jul 3.
6
Immune System, Friend or Foe of Oncolytic Virotherapy?
Front Oncol. 2017 May 23;7:106. doi: 10.3389/fonc.2017.00106. eCollection 2017.
7
Past, Present and Future of Oncolytic Reovirus.
Cancers (Basel). 2020 Oct 31;12(11):3219. doi: 10.3390/cancers12113219.
8
Design and application of oncolytic viruses for cancer immunotherapy.
Curr Opin Biotechnol. 2020 Oct;65:25-36. doi: 10.1016/j.copbio.2019.11.016. Epub 2019 Dec 23.
9
Oncolytic viruses and their application to cancer immunotherapy.
Cancer Immunol Res. 2014 Apr;2(4):295-300. doi: 10.1158/2326-6066.CIR-14-0015.
10
Oncolytic viruses as therapeutic cancer vaccines.
Mol Cancer. 2013 Sep 11;12(1):103. doi: 10.1186/1476-4598-12-103.
引用本文的文献
1
High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.
Sci Rep. 2024 Nov 16;14(1):28284. doi: 10.1038/s41598-024-76855-3.
2
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Mol Ther. 2023 Nov 1;31(11):3176-3192. doi: 10.1016/j.ymthe.2023.09.017. Epub 2023 Sep 27.
3
Optimal delivery of RNA interference by viral vectors for cancer therapy.
Mol Ther. 2023 Nov 1;31(11):3127-3145. doi: 10.1016/j.ymthe.2023.09.012. Epub 2023 Sep 20.
4
Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy.
Mol Ther Oncolytics. 2022 Apr 19;25:146-159. doi: 10.1016/j.omto.2022.04.004. eCollection 2022 Jun 16.
5
Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Hum Vaccin Immunother. 2022 May 31;18(3):1971015. doi: 10.1080/21645515.2021.1971015. Epub 2021 Dec 9.
6
Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.
JCO Precis Oncol. 2021 Apr 27;5. doi: 10.1200/PO.21.00003. eCollection 2021.
7
Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.
Oncol Lett. 2019 Nov;18(5):5534-5542. doi: 10.3892/ol.2019.10901. Epub 2019 Sep 20.
8
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.
Biomedicines. 2019 Aug 30;7(3):66. doi: 10.3390/biomedicines7030066.
9
Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient.
Clin Case Rep. 2019 May 8;7(6):1191-1196. doi: 10.1002/ccr3.2182. eCollection 2019 Jun.
10
Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
J Ovarian Res. 2019 Feb 15;12(1):18. doi: 10.1186/s13048-019-0493-5.
本文引用的文献
1
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19.
2
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.
3
Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.
4
PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
Oncol Rep. 2014 Apr;31(4):1581-8. doi: 10.3892/or.2014.3020. Epub 2014 Feb 11.
5
Immunosuppressive treatments in multiple sclerosis.
Handb Clin Neurol. 2014;122:503-11. doi: 10.1016/B978-0-444-52001-2.00022-4.
6
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
Int J Cancer. 2014 Sep 1;135(5):1238-46. doi: 10.1002/ijc.28747. Epub 2014 Feb 18.
7
From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.
PLoS Pathog. 2014 Jan;10(1):e1003836. doi: 10.1371/journal.ppat.1003836. Epub 2014 Jan 16.
8
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
Br J Cancer. 2014 Jan 7;110(1):83-93. doi: 10.1038/bjc.2013.695. Epub 2013 Nov 26.
9
Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
Exp Hematol. 2013 Dec;41(12):1038-49. doi: 10.1016/j.exphem.2013.09.005. Epub 2013 Sep 22.
10
Exploiting tumor epigenetics to improve oncolytic virotherapy.
Front Genet. 2013 Sep 20;4:184. doi: 10.3389/fgene.2013.00184.
Zotero 插件